GlassScriptPhysician profile
Kellen Travis Jex
NPI 1952698532
$9,678.16
in general payments reported to CMS, 2019-2025
22 companies · $5,232 in 2025
The $5,232 reported for 2025 was more than what 91% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $737 · 2020: $123 · 2021: $29.64 · 2022: $596 · 2023: $727 · 2024: $2,234 · 2025: $5,232.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $4,945 · Food and Beverage: $3,248.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $4,945.00 |
| Food and Beverage | $3,248.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $5,207.92 | 2024-2025 | Voquezna |
| Abbvie INC. | $1,816.96 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $852.53 | 2019-2024 | Xifaxan, Trulance, Plenvu |
| Boston Scientific Corporation | $269.45 | 2019-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $210.30 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Aimmune Therapeutics, INC. | $205.05 | 2024-2025 | Zenpep |
| Regeneron Healthcare Solutions, INC. | $147.87 | 2023-2025 | Dupixent |
| Ardelyx, INC. | $144.31 | 2024-2025 | Ibsrela |
| Janssen Biotech, INC. | $121.83 | 2024-2025 | Stelara, Tremfya |
| Intercept Pharmaceuticals, INC. | $120.59 | 2023-2025 | Ocaliva |
| Qol Medical, LLC | $87.85 | 2019-2024 | Sucraid |
| Nestle Healthcare Nutrition INC. | $84.56 | 2022-2023 | |
| Genzyme Corporation | $81.50 | 2024-2025 | |
| Madrigal Pharmaceuticals | $57.54 | 2024-2025 | Rezdiffra, Resmetirom |
| Lilly USA, LLC | $50.81 | 2025 | Omvoh |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $48.99 | 2019 | |
| Novo Nordisk INC | $36.74 | 2020-2025 | Wegovy, Saxenda |
| Gilead Sciences, INC. | $34.96 | 2022-2025 | |
| Pfizer INC. | $29.87 | 2019-2022 | |
| Braintree Laboratories, INC. | $25.91 | 2019-2020 | |
| Allergan, INC. | $23.80 | 2019 | |
| Merck Sharp & Dohme LLC | $18.82 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kellen Jex listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.